◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral SKIP-FOR-NOW HIGH

Suvorexant

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW HIGH

First DORA approved (2014, Merck), most real-world data and longest tail of post-market evidence — but the 12-hour half-life produces measurably more next-day grogginess than daridorexant's 8 hr, and the 2025 network meta-analysis ranked it weakest of the three approved DORAs on subjective TST. Dylan does not have insomnia (chronotype problem, not sleep-onset problem), and if a DORA is ever needed, daridorexant is the better-fit tool for a brain-priority 20yo. Verdict would shift to OPTIONAL only if (a) daridorexant becomes unavailable or unaffordable, (b) a sleep-maintenance indication emerged where suvorexant's longer half-life is actually wanted, or (c) the long-term amyloid-clearance signal (Lucey 2023) gets replicated and a 20-year prevention case opens up.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-FOR-NOW

    Wrong DORA for this profile. The 12-hour half-life produces measurable next-day cognitive impairment that directly conflicts with 6-12hr cognitive output goals. Daridorexant (8 hr) is the cleaner tool if any DORA is needed; suvorexant offers no advantage here unless cost is the binding constraint (it isn't for Dylan at his stated budget). Generic availability lowering cost to $80-180/mo doesn't change this because the next-day fog is the binding cost, not the dollar cost.

  • 30-50, executive maintenance
    OPTIONAL-ADD

    if cost-constrained. Generic availability changes the calculus modestly — if insurance won't cover daridorexant and cash $300-500/mo is prohibitive, generic suvorexant at $80-180/mo is a reasonable down-tier. Accept the morning grogginess tradeoff or dose at 10 mg only.

  • 50+, mild cognitive decline
    OPTIONAL-ADD

    with caveats. The Lucey 2023 amyloid-clearance signal is *most relevant* in this age band, and suvorexant has the actual data (daridorexant doesn't have an equivalent CSF Aβ trial yet). Counterargument: 50+ population is also more vulnerable to next-day cognitive cost from a 12-hour half-life. Dose at 10 mg and monitor. Not a primary pick — daridorexant is still cleaner — but the only DORA with direct preliminary AD-relevant biomarker data.

  • Anxiety-prone
    OPTIONAL-ADD

    Same DORA-class advantage over benzos for chronic-use anxiety patients. The vivid-dream side effect and slightly higher suicidal-ideation signal vs daridorexant make it a worse fit than daridorexant for this population. Pick daridorexant if available.

  • High athletic load, tested status
    OPTIONAL-ADD

    Not WADA-banned. Same architecture-preservation argument as daridorexant. The morning grogginess hurts AM training output more than daridorexant would; if athletic schedule allows late dosing and lighter AM loads on dose-nights, defensible. Most lifters/athletes get more value from sleep hygiene + magnesium + tryptophan.

  • Sleep-disordered (chronic insomnia, primary)
    STRONG-CANDIDATE

    if cost-constrained, else OPTIONAL. This is the on-label population. Generic availability + AASM 2022 endorsement + 12-year safety tail make suvorexant the cheapest evidence-backed DORA. If a chronic-insomnia patient cannot afford daridorexant, suvorexant 10 mg is a defensible first move. Sleep-onset-dominant insomnia → lemborexant. Sleep-maintenance-dominant + cost-constrained → suvorexant. Both → daridorexant if affordable.

  • Recovery-focused (post-injury, post-illness)
    OPTIONAL-ADD

    if cost-constrained. Architecture preservation matters for tissue repair. Same logic as athletic case — accept the morning grogginess tradeoff or pick daridorexant.

  • Strength/anabolic-focused
    OPTIONAL-ADD

    N3 sleep is GH peak window; DORAs preserve N3. Cost-constrained users get most value from suvorexant generic; brain/AM-training priority users go daridorexant.

▸ Subjective experience (deep)
  • Onset: ~30-60 min to perceptible relaxation; Tmax ~2 hr (delayed by food). Take ~30 min before bed on empty stomach.
  • Peak: ~2-3 hours post-dose. Like other DORAs, the feel is "wake drive turned off" rather than sedation. Less of a knock-out feeling than zolpidem; more "the mind has nothing to do."
  • Duration: Effective overnight; wears off slowly (12-hour half-life = ~6-8 hours of clinically meaningful overlap into the morning).
  • Morning: Grogginess is the signature complaint. Most users describe a 1-2 hour "fog" after waking that fades through coffee/light/movement. Significantly more than daridorexant (which clears by morning) and somewhat less than lemborexant (which lingers longer for some). Driving studies show measurable impairment 9 hr post-dose at 20 mg.
  • Sleep maintenance: Strong signal — fewer middle-of-night awakenings.
  • Sleep onset: Modest-to-moderate effect; lemborexant has the better onset signal in the NMA.
  • Dreams: Vivid, sometimes disturbing dreams are more common than with daridorexant. Some users actively like this (lucid dreaming community has a small cohort that uses suvorexant for this); most users find it neutral or mildly off-putting.
  • Sleep paralysis / hypnagogic hallucinations: Reported in ~1-3% of users. Self-limited, benign, but frightening.
  • No "drugged" feeling during sleep itself — the DORA-class subjective separator from benzos/Z-drugs holds.
  • Discontinuation: No rebound, no withdrawal — class property.

Honest variability: ~10-20% of users get minimal benefit (likely non-orexin-driven insomnia). Body habitus matters — heavier users may need 20 mg over 10/15 mg. CYP3A4 polymorphisms drive significant inter-individual exposure variation (see Pharmacogenomics).

▸ Tolerance + cycling deep dive
  • Tolerance buildup: None demonstrated through 12 months of nightly use (phase 3 + extension data). Class property — DORAs do not produce tachyphylaxis.
  • Recommended cycle: None required. PRN or nightly both fine. PRN preferred for non-chronic-insomnia users.
  • Reset protocol if needed: Not applicable.
▸ Stacking deep dive

Synergistic with

  • L-tryptophan: Tryptophan substrate-side, suvorexant receptor-side. Mechanistically independent. Same logic as daridorexant.
  • Magnesium glycinate (V4): independent NMDA/glycinergic mechanism. Safe stack.
  • Apigenin (V4): GABA-A PAM at low doses. Compatible.
  • L-theanine (V4): GABA modulation. Compatible.

Avoid stacking with

  • Alcohol: additive PD impairment + PK shift. Class warning. (Irrelevant for Dylan zero-alcohol baseline.)
  • Strong CYP3A4 inhibitors (clarithromycin, ketoconazole, itraconazole, ritonavir, nefazodone, large-volume grapefruit juice): AVOID — labeling explicitly contraindicates concomitant use with strong CYP3A4 inhibitors at any dose. Exposure can rise 4-5×.
  • Moderate CYP3A4 inhibitors (diltiazem, erythromycin, fluconazole, fluvoxamine, verapamil, ciprofloxacin): Maximum 5 mg dose with moderate inhibitors per FDA label. This is more restrictive than daridorexant's 25-mg-cap rule.
  • Strong CYP3A4 inducers (carbamazepine, phenytoin, rifampin, St. John's wort, efavirenz): suvorexant becomes ineffective. Don't combine.
  • Other CNS depressants (benzos, Z-drugs, opioids, gabapentinoids, phenibut, GHB): additive sedation/respiratory risk. Don't double-stack hypnotics.
  • Muscle relaxants (cyclobenzaprine, baclofen, methocarbamol, tizanidine, carisoprodol): specific FDA-labeled additive sedation concern for suvorexant. Worth knowing if Dylan ever needs a muscle relaxant for MMA injury — pick a non-overlap timing window.
  • Bromantane same evening (V5 plan): functionally counterproductive — bromantane wake-supportive, suvorexant sleep-supportive. Take bromantane AM only.
  • Modafinil same calendar day: PK okay if modafinil dosed before noon and suvorexant after 10 PM, but the 12-hour half-life of suvorexant overlaps modafinil's morning window the next day, which is exactly the cognitive-cost problem. This is the central reason suvorexant is the wrong DORA for a modafinil user.
  • Selank same evening: mildly nootropic-alerting; blunts suvorexant's effect.

Neutral / safe co-administration

  • DHA / fish oil, NAC, citicoline, PS, curcumin, rhodiola, D3+K2, vitamin C, beta-alanine, creatine — no documented interactions; all V4 stack components are safe co-admin.
  • Caffeine — not a hard interaction but functionally counterproductive in the 8-12 hr window before suvorexant dosing.
▸ Drug interactions deep dive

Suvorexant is a CYP3A4 substrate (>95% of clearance), with minor CYP2C19 contribution. Stack design hinges almost entirely on CYP3A4 modulation status.

Suvorexant as a substrate:

  • Strong CYP3A4 inhibitors → CONTRAINDICATED. FDA labeling explicitly: "Concomitant use with strong CYP3A inhibitors is not recommended." Stricter than daridorexant.
  • Moderate inhibitors → max 5 mg dose. Significantly more restrictive than daridorexant's max-25 mg rule. Reflects the longer half-life amplifying any exposure increase.
  • Strong inducers → likely subtherapeutic, switch class.
  • Grapefruit juice in routine quantities — same gut CYP3A4 inhibition concern. Avoid same-day.

Suvorexant as a perpetrator:

  • Mild CYP3A4 inhibition at 40 mg (above current 20 mg max). Negligible at 10-20 mg.
  • Minor digoxin interaction (P-gp substrate effect) — slight digoxin AUC increase. Clinically meaningless in non-digoxin users.

Other relevant:

  • Renal impairment: PK unchanged. No dose adjustment.
  • Hepatic impairment: Mild → no adjustment. Moderate → exposure rises ~2×; not formally restricted but use lower doses. Severe → not studied; avoid.
  • Age ≥65: Slightly higher exposure; FDA label suggests starting at 10 mg in elderly.
  • Body weight: Females and obese patients showed higher exposure in PK modeling — labeling advises starting low (10 mg) in these groups.
▸ Pharmacogenomics
  • CYP3A4 polymorphisms are the dominant axis, identical conceptual situation to daridorexant.
    • CYP3A4*22 (rs35599367, T allele): reduced enzyme activity → higher suvorexant exposure → start at 10 mg, do not titrate without observation. Frequency ~5-7% in Europeans.
    • CYP3A5*3 (rs776746, G allele): the *3 allele is non-functional. Most Europeans (~90%) and Asians (~70%) are *3/*3 homozygotes (CYP3A5 non-expressors), shifting metabolic load to CYP3A4. Dylan's Nordic/British ancestry → very likely CYP3A5 non-expressor.
  • CYP2C19 polymorphisms (PM phenotype, ~3% Caucasians, ~15-20% East Asians): minor effect on suvorexant exposure since CYP2C19 contributes <5% of clearance. Not clinically actionable.
  • 23andMe raw data check (June 2026): if Dylan is CYP3A4*22 carrier, this is identical to the daridorexant pharmacogenomic flag — start lower, observe before titrating.
  • No direct OX1/OX2 polymorphism implications clinically established for DORA response.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
US Rx (insurance covered) Merck/CVS/Walgreens $25-100 copay/mo high Better insurance coverage than daridorexant due to longer market presence; Medicare Part D often covers
US Rx (cash, GoodRx, brand) Any pharmacy $250-450/mo brand high Brand Belsomra retail ~$400-450/mo; GoodRx discounts variable
US Rx (cash, generic suvorexant) Any pharmacy $80-180/mo as of 2025-2026 high Generic suvorexant launched late 2024 / early 2025 — first DORA with generic competition. Significantly lower cost than daridorexant or lemborexant (both still patent-protected).
US Rx (telehealth) Klarity, sleep telehealth Visit fee + Rx high Schedule IV — most telehealth platforms write it. DEA telehealth flexibilities through Dec 31, 2026.
Indian generic Various Indian pharmacies (Ladsons, AfinilExpress, ModafinilXL adjacent) $40-80/mo equivalent medium-low Indian generic suvorexant exists but quality control varies; not as standardized as Indian modafinil ecosystem. COA verification recommended.
Canadian pharmacy Canadian pharmacy $150-250/mo medium Cross-border shipping legal gray zone.

Practical sourcing for Dylan (US, hypothetical only — not recommended): Generic suvorexant via US Rx is now ~$80-180/mo, which is meaningfully cheaper than daridorexant's $300-500/mo. This is the only realistic argument for picking suvorexant over daridorexant — and it loses to the cognitive-cost differential for a brain-priority 20yo. If cost were the dominant constraint (it isn't for Dylan), suvorexant becomes defensible.

▸ Biomarkers to track (deep)

Baseline (before starting)

  • Sleep diary 14 days minimum: sleep onset, wake time, subjective TST, awakenings, morning alertness 0-10, dream intensity/disturbance 0-10 (specifically because suvorexant produces more vivid dreams).
  • Optional actigraphy / wearable (Oura, Whoop, Apple Watch, Colmi R06).
  • Insomnia Severity Index (ISI) — pre-trial baseline.
  • Epworth Sleepiness Scale — daytime sleepiness baseline, especially relevant given the longer half-life.
  • ALT/AST (liver baseline given heavy CYP3A4 hepatic load).
  • Suicidal ideation screening (PHQ-9 item 9 or C-SSRS) — prescribers should baseline this before initiation.

During use

  • Sleep diary continued through trial (4-6 weeks minimum).
  • ISI repeat at week 4.
  • Morning alertness 0-10 every morning — most important biomarker for assessing whether suvorexant's grogginess profile is acceptable.
  • Dream intensity/disturbance log — track for parasomnia, hallucination, sleep paralysis episodes.
  • Cognitive task performance if available (n-back, reaction time) — track day 7, 14, 28 vs baseline. Especially important for suvorexant given the literature-documented driving impairment.
  • Wearable sleep stage data (REM%, N3%, TST, fragmentation).

Post-cycle (if discontinuing)

  • No rebound expected but track sleep diary 2 weeks post.
  • Vivid dreams typically resolve within days of discontinuation.
▸ Controversies / open debates Live debate
  1. The Lucey 2023 amyloid signal — promising but small. A single trial, n=38, healthy 45-65yo, two nights of dosing, showing ~10-15% reduction in CSF Aβ40/42 vs placebo. This is mechanism-supportive, not clinical-outcome data. The leap from "lowers CSF amyloid acutely" to "prevents AD over decades" is large and unbridged. Multiple longer-term trials are now running (NCT04162769, NCT05476783, others) testing whether chronic DORA use reduces amyloid plaque burden on PET imaging in 50-70yo healthy adults over 1-3 years. This is the single most important open question for the DORA class long-term. If positive, the calculus on chronic DORA use in 30-50yo brain-priority users could shift dramatically. If null, suvorexant remains a "treat your insomnia, that's it" drug. Track over 5-10 year horizon, not Dylan-decision-relevant today.
  2. Suvorexant suicidal-ideation signal — class warning or molecule-specific? FDA medical review noted a numerical excess of suicidal ideation events in suvorexant trials vs placebo (small numbers, not formally significant, but meaningful enough for regulators). Daridorexant's pivotal trials did not show this signal. Whether this is a true molecule-specific liability or a chance finding in a larger / older dataset is unresolved. Conservative read: prefer daridorexant in any patient with depression/anxiety history.
  3. Generic suvorexant quality. Generic launched late 2024 / early 2025. As of 2026-05, post-market monitoring of generic-vs-brand bioequivalence is still accumulating. Anecdotal reports on Reddit suggest some generic batches feel weaker than brand. Standard concern for any newly genericized CNS drug; should resolve within 12-18 months of generic availability.
  4. DORAs and chronotype migration — same null-evidence hole as daridorexant. No DORA has data supporting use for delayed sleep phase syndrome or late-chronotype phase advance. Suvorexant is even worse-suited than daridorexant for this off-label indication because the 12-hour half-life pushes effect into morning, fighting the very phase advance you're trying to install.
  5. Vivid-dream prominence — feature or bug? A small lucid-dreaming community uses suvorexant intentionally. For most users, vivid dreams are mild-to-neutral. For a minority, disturbing dreams are a discontinuation reason. Mechanism: longer half-life + REM preservation = more REM exposure to OX2 antagonism, and orexin modulates REM-active circuits.
▸ Verdict change log
  • 2026-05-06 — Initial verdict: SKIP-FOR-NOW. First DORA, deepest data tail, AASM-recommended, generic-available — but the 12-hour half-life produces measurably more next-day grogginess than daridorexant (8 hr) without proportionally better sleep effects, and the 2025 NMA ranked it weakest of the three DORAs on subjective TST. Dylan does not have insomnia (chronotype problem, not sleep-onset problem). If a DORA is ever needed, daridorexant is the better-fit tool. Lucey 2023 amyloid signal is interesting for a long-horizon AD-prevention thesis but not Dylan-decision-relevant today (small trial, healthy 45-65yo population, mechanism-only endpoint).
▸ Open questions / gaps Open
  1. Lucey 2023 replication and clinical extension — are the long-term DORA-and-amyloid trials (NCT04162769, NCT05476783) going to show plaque reduction on PET? 5-10 year answer.
  2. CYP3A4*22 status — pending 23andMe results June 2026. Same flag as for daridorexant.
  3. Generic suvorexant bioequivalence — accumulating post-market data through 2026-2027.
  4. Suicidal ideation signal — molecule-specific or class? Probably resolved in next post-market meta-analysis.
  5. Real-world chronotype-migration use — almost certainly null even if anyone studies it; not worth pursuing.
▸ Sources (full, with our context)
Back to compact view